Akebia Therapeutics, Inc.

Akebia Therapeutics develops and commercializes therapeutics for kidney diseases. Lead product Vafseo (vadadustat) treats anemia due to chronic kidney disease in dialysis-dependent and non-dialysis patients. Offers Auryxia for serum phosphorus level control and iron deficiency anemia treatment. Product pipeline includes AKB-9090 for critical-care indications and AKB-10108 for premature birth-related conditions. Has collaborations with Mitsubishi Tanabe Pharma and Janssen Pharmaceutica NV. Incorporated in 2007, headquartered in Cambridge, Massachusetts.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

2.8 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0

Akebia Therapeutics, Inc.

Overview

Strengths

Weaknesses

Key Financial Data